HK1019751A1 - Tissue specific expression of retinoblastoma protein. - Google Patents

Tissue specific expression of retinoblastoma protein.

Info

Publication number
HK1019751A1
HK1019751A1 HK99104577A HK99104577A HK1019751A1 HK 1019751 A1 HK1019751 A1 HK 1019751A1 HK 99104577 A HK99104577 A HK 99104577A HK 99104577 A HK99104577 A HK 99104577A HK 1019751 A1 HK1019751 A1 HK 1019751A1
Authority
HK
Hong Kong
Prior art keywords
specific expression
retinoblastoma protein
tissue specific
retinoblastoma
protein
Prior art date
Application number
HK99104577A
Other languages
English (en)
Inventor
Douglas Antelman
Richard J Gregory
Kenneth N Wills
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/801,092 external-priority patent/US6074850A/en
Application filed by Canji Inc filed Critical Canji Inc
Publication of HK1019751A1 publication Critical patent/HK1019751A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK99104577A 1996-11-15 1999-10-15 Tissue specific expression of retinoblastoma protein. HK1019751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75151796A 1996-11-15 1996-11-15
US08/801,092 US6074850A (en) 1996-11-15 1997-02-14 Retinoblastoma fusion polypeptides
PCT/US1997/021821 WO1998021228A1 (en) 1996-11-15 1997-11-13 Tissue specific expression of retinoblastoma protein

Publications (1)

Publication Number Publication Date
HK1019751A1 true HK1019751A1 (en) 2000-02-25

Family

ID=27115430

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99104577A HK1019751A1 (en) 1996-11-15 1999-10-15 Tissue specific expression of retinoblastoma protein.

Country Status (16)

Country Link
US (2) US6902731B1 (xx)
EP (1) EP0948520B1 (xx)
JP (1) JP4109721B2 (xx)
KR (1) KR100336551B1 (xx)
CN (1) CN100338219C (xx)
AT (1) ATE286908T1 (xx)
AU (1) AU723660B2 (xx)
BR (1) BR9712767B1 (xx)
CA (1) CA2271478C (xx)
DE (1) DE69732246T2 (xx)
ES (1) ES2234040T3 (xx)
HK (1) HK1019751A1 (xx)
HU (1) HU226662B1 (xx)
IL (1) IL129922A0 (xx)
NZ (1) NZ335738A (xx)
WO (1) WO1998021228A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054969A2 (en) * 1998-02-12 2000-11-29 Curagen Corporation Retinoblastoma protein complexes and retinoblastoma interacting proteins
WO2000022124A2 (en) * 1998-10-15 2000-04-20 Canji, Inc. Methods and compositions to induce antitumor response
AU758354B2 (en) * 1998-10-15 2003-03-20 Canji, Inc. Selectively replicating viral vectors
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6649158B1 (en) 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
WO2002050101A1 (en) * 2000-12-19 2002-06-27 The Council Of The Queensland Institute Of Medical Research Retinoblastoma-binding protein
US6866994B2 (en) * 2001-05-30 2005-03-15 Neomatrix, Llc Noninvasive intraductal fluid diagnostic screen
CN103463646A (zh) * 2013-09-19 2013-12-25 浙江大学 E2f1蛋白在制备诊断和治疗骨肉瘤药物中的应用
US9895446B2 (en) 2015-07-14 2018-02-20 Professional Compounding Centers Of America Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
ES2221920T3 (es) 1992-04-03 2005-01-16 The Regents Of The University Of California Sistema de liberacion de polinucleotidos de autoensamblaje que comprende un peptido cationico anfipatico.
AU3940293A (en) 1992-04-03 1993-11-08 Alexander T. YOUNG Gene therapy using targeted viral vectors
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
ZA947065B (en) * 1993-09-13 1995-05-03 Univ California Therapeutic use of the retinoblastoma susceptibility gene product
US5473056A (en) * 1993-10-13 1995-12-05 Merck & Co., Inc. E2F-2, a novel mammalian transcription factor

Also Published As

Publication number Publication date
IL129922A0 (en) 2000-02-29
HU226662B1 (en) 2009-06-29
CN100338219C (zh) 2007-09-19
EP0948520B1 (en) 2005-01-12
AU5589998A (en) 1998-06-03
ES2234040T3 (es) 2005-06-16
JP2001503638A (ja) 2001-03-21
KR100336551B1 (ko) 2002-05-11
DE69732246T2 (de) 2005-12-08
ATE286908T1 (de) 2005-01-15
CA2271478C (en) 2003-02-04
AU723660B2 (en) 2000-08-31
HUP9903864A3 (en) 2001-09-28
DE69732246D1 (de) 2005-02-17
CA2271478A1 (en) 1998-05-22
EP0948520A1 (en) 1999-10-13
WO1998021228A1 (en) 1998-05-22
JP4109721B2 (ja) 2008-07-02
KR20000053323A (ko) 2000-08-25
US6902731B1 (en) 2005-06-07
CN1244870A (zh) 2000-02-16
EP0948520A4 (en) 2003-03-12
BR9712767B1 (pt) 2010-11-30
NZ335738A (en) 2001-02-23
US6379927B1 (en) 2002-04-30
HUP9903864A2 (hu) 2001-04-28
BR9712767A (pt) 1999-10-26

Similar Documents

Publication Publication Date Title
AU5671594A (en) Human tissue factor related dna segments, polypeptides and antibodies
NZ506783A (en) Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
AU6549898A (en) Method for the broad based treatment of infections, especially infections of organs such as the skin and vagina
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
IL110464A0 (en) Novel proteins for the diagnosis, imaging, and therapy of human cancer
HU9401260D0 (en) Fema gene of staphylococcus epidermis, fema protein, and vectors and microorganisms comprising the fema gene
HK1019751A1 (en) Tissue specific expression of retinoblastoma protein.
EP0209543A4 (en) FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE.
HU9802132D0 (en) Biphenyl-sulfonyl-cyanamides, process for producing them and their medical use
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
DE69734464D1 (de) Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon
EP0742019A4 (en) GLASS MATERIAL, REPLACEMENT MATERIAL FOR LIVING TISSUE AND TOOTH REINFORCING MATERIAL
AU9764698A (en) A fusion protein of hegf and human angiogenin, and process for preparing the same
AU3241895A (en) Apoptosis related protein bcl-y, and methods of use thereof
AU3140697A (en) The spindly gene, methods of identification and use
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
DE69535337D1 (de) Transkriptionsfaktor e2f-5
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
AU3118095A (en) Dna sequences coding for the human proteins tx and ty related to the interleukin-1beta converting enzyme
AU4037299A (en) Genetically-modified fibroblasts and the use thereof
WO1998024482A3 (de) Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung
AU5484598A (en) Processed polypeptides with il-16 activity, processes for their production and their use

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141113